News

Barchart on MSN4d
What to Expect From Regeneron's Next Quarterly Earnings Report
With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...
Regeneron price target lowered to $547 from $575 at BofA
BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower ...
Crain's New York Business16d
New York pharma stocks hold steady amid market plunge
The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President ...
Regeneron: Still A Biotech Juggernaut
Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...
Regeneron Gets FDA Priority Review for Expanded Eylea HD Use
Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug.
Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU
Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...
Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...
FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion
FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.